V122I transthyretin variant in elderly black Americans.

Transthyretin Cardiac Amyloidosis in Black Americans. Circ Heart Fail (2016) 0.75

V122I transthyretin variant in elderly black Americans. N Engl J Med (2015) 0.75

The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med (2015) 3.36

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64

Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19

Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54

Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47

T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21

Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07

Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86

Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging (2013) 3.53

Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35

Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74

Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum (2002) 2.58

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34

Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26

Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20

Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum (2002) 2.19

Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01

Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood (2012) 1.80

Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.61

Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart (2012) 1.56

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood (2006) 1.54

Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51

Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci (2013) 1.43

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica (2008) 1.38

Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant (2004) 1.36

Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2009) 1.34

Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med (2006) 1.32

Human plasma fibrinogen is synthesized in the liver. Blood (2006) 1.27

Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med (2012) 1.26

Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging (2012) 1.25

Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat (2014) 1.23

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood (2005) 1.22

Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol (2011) 1.21

Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc (2013) 1.20

AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood (2008) 1.20

Perspectives in treatment of AL amyloidosis. Br J Haematol (2007) 1.17

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol (2006) 1.13

Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis. Amyloid (2005) 1.13

Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol (2006) 1.12

Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol (2004) 1.11

The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum (2011) 1.09

Systemic amyloidosis in England: an epidemiological study. Br J Haematol (2013) 1.08

Decreasing incidence of AA amyloidosis in Spain. Eur J Clin Invest (2013) 1.08

Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol (2008) 1.07

Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol (2006) 1.06

Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol (2011) 1.04

Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol (2002) 1.04

Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin. J Biol Chem (2013) 1.04

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol (2010) 1.04

The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J (2012) 1.03

Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med (2005) 1.02

Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci U S A (2013) 1.01

Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol (2014) 1.01

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther (2011) 1.00

Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev (2015) 1.00

Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci U S A (2009) 0.99

Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg (2008) 0.96

AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum (2013) 0.94

The significance of paired MEFV mutations in individuals without symptoms of familial Mediterranean fever. Eur J Hum Genet (2002) 0.93

Brief Report: whole-exome sequencing revealing somatic NLRP3 mosaicism in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheumatol (2014) 0.93

Cardiac transthyretin amyloidosis. Heart (2012) 0.93

Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol (2013) 0.93

Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Res Ther (2009) 0.91

The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis (2002) 0.91

Amyloidosis. Ann Clin Biochem (2012) 0.91